SLC13A5 Antibody

Datasheet

Code	CSB-PA768239LA01HU
Size	US$166
	Order now
Image	Western Blot Positive WB detected in: HepG2 whole cell lysate(30µg), Raji whole cell lysate(30µg), JK whole cell lysate(30µg), LO2 whole cell lysate(30µg), HT29 whole cell lysate(30µg), 293 whole cell lysate(30µg),Mouse Liver tissue lysate(30µg),Rat Liver tissue lysate(30µg) All lanes: SLC13A5 antibody at 1:1000 Secondary Goat polyclonal to rabbit IgG at 1/40000 dilution Predicted band size: 64,59,62 kDa Observed band size: 64 kDa Exposure time: 120s IHC image of CSB-PA768239LA01HU diluted at 1:100 and staining in paraffin-embedded human prostate cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Secondary antibody only control: uses 1% BSA instead of primary antibody.
Promotion
Have Questions?	Leave a Message or Start an on-line Chat

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Full Product Name

Rabbit anti-Homo sapiens (Human) SLC13A5 Polyclonal antibody

Uniprot No.

Q86YT5

Target Names

SLC13A5

Alternative Names

Na(+)/citrate cotransporter antibody; NaC2/NaCT antibody; NaCT antibody; Novel solute carrier family 13 (sodium dependent dicarboxylate transporter) (Slc13a2 or 3) member antibody; S13A5_HUMAN antibody; Slc13a5 antibody; Sodium coupled citrate transporter antibody; Sodium-coupled citrate transporter antibody; Sodium-dependent citrate transporter antibody; Solute carrier family 13 (sodium dependent citrate transporter); member 5 antibody; Solute carrier family 13 member 5 antibody

Raised in

Rabbit

Species Reactivity

Human, Mouse, Rat

Immunogen

Synthesized peptide derived from human S13A5

Immunogen Species

Homo sapiens (Human)

Clonality

Polyclonal

Isotype

IgG

Purification Method

Antigen affinity purification

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Form

Liquid

Tested Applications

ELISA, WB, IHC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

The product CSB-PA768239LA01HU is a polyclonal antibody against the SLC13A5 protein. It is raised in the rabbit immunized by a partial recombinant protein mapping within amino acids 156-204 of human SLC13A5 protein. This SLC13A5 antibody is available as the unconjugated IgG isoform. It can react with SLC13A5 proteins from human, mouse, and rat samples. It has undergone protein G purification and reaches over 95% in purity. Multiple and rigorous validations performed in this SLC13A5 antibody demonstrated that it can recognize SLC13A5 protein in ELISA, IHC, IF, and WB applications.

The target protein SLC13A5 mainly transports citrate and other dicarboxylic acids from the extracellular environment into the cell, where they can be metabolized by the mitochondria to generate ATP and regulate various metabolic pathways. Mutations in the SLC13A5 gene can cause a rare neurological disorder epileptic encephalopathy, which is characterized by seizures and cognitive impairment.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function

High-affinity sodium/citrate cotransporter that mediates citrate entry into cells. Transports citrate in a Na(+)-dependent manner, transport process is electrogenic and recognizes the trivalent form of citrate rather than the divalent form. Although citrate is its main substrate, other intermediates of the citric acid cycle, such as succinate, fumarate, malate, oxaloacetate and alpha-ketoglutarate can serve as substrates but with a much lower affinity compared to citrate. Shows a substrate sensitivity in the order of citrate > malate ~ alpha-ketoglutarate > succinate ~ fumarate > oxaloacetate ~ isocitrate. Shows substantial citrate transporter activity when sodium ions are replaced by either potassium or choline ions. Transport activity is potentiated by lithium ions in the presence of low concentrations of citrate but is inhibited by lithium ions in the presence of high concentrations of citrate. Involved in the regulation of citrate levels in the brain.

Gene References into Functions

SLC13A5 is the second major gene associated with the clinical diagnosis of KTZS. PMID: 27600704
Data suggest that SLC13A5 plays a role in progression/cell proliferation of human hepatocellular carcinoma cells; here, RNA interference using shRNA against SLC13A5 decreased tumor burden in treatment of hepatocarcinoma in a xenograft tumor model in nude mice. PMID: 28655760
Data suggest that SLC13A5 plays a role in progression/proliferation of human hepatocellular carcinoma cells; RNA interference using shRNA against SLC13A5 decreased tumor burden in treatment of hepatocarcinoma in a xenograft tumor model in nude mice. [REVIEW] PMID: 28821606
Study identified additional SLC13A5 mutations in patients with chronic epilepsy starting in the neonatal period, with the mutations producing inactive Na+/citrate transporters. PMID: 27261973
Studies show that SLC13A5 is a transporter in the plasma membrane that mediates the uptake of citrate into cells. It is expressed in hepatocytes, neurons, and spermatozoa. Its loss-of-function mutations are associated with neonatal epilepsy in humans. This is a single-gene disease with epilepsy resulting solely from the inactivity of SLC13A5. [review] PMID: 28264506
In infants presenting with therapy resistant seizures in the first days after birth, without a clear history of hypoxic-ischemic encephalopathy, but with Punctate White Matter Lesions on their neonatal MRI, a diagnosis of SCL13A5 related epileptic encephalopathy should be considered. PMID: 27913086
Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5). PMID: 26620127
Eight patients from four families with SLC13A5 mutation are described. They have neonatal epilepsy, tooth hypoplasia, and developmental delay. PMID: 26384929
SLC13A5 is a novel target gene of PXR and may contribute to drug-induced steatosis and metabolic disorders in humans. PMID: 25628225
Screening of 68 additional unrelated individuals with early-onset epileptic encephalopathy for SLC13A5 mutations led to identification of one additional subject with heterozygous mutations of SLC13A5 and a similar clinical presentation as index subjects PMID: 24995870
Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) PMID: 20379614
This paper describes the cloning and functional characterization of the human Na(+)-coupled citrate transporter (NaCT). PMID: 12445824
mediates the utilization of extracellular citrate for fat synthesis in human liver cells, and that the process is stimulated by lithium PMID: 12826022
Expression and function of NaCT in a cell line and in primary hepatocytes. PMID: 16973915

Hide All

Involvement in disease

Epileptic encephalopathy, early infantile, 25 (EIEE25)

Subcellular Location

Cell membrane; Multi-pass membrane protein.

Protein Families

SLC13A/DASS transporter (TC 2.A.47) family, NADC subfamily

Tissue Specificity

Expressed most predominantly in the liver, with moderate expression detectable in the brain and testis.

Database Links

HGNC: 23089

OMIM: 608305

KEGG: hsa:284111

STRING: 9606.ENSP00000406220

UniGene: Hs.399496

Promotions

Email: [email protected]
Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?

Related pathways

Target Therapy

Call us

301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)

[email protected]

Address

7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA

Join us with

Subscribe newsletter

Leave a message

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Place an order now

I. Product details

Product name *

Code *

Size *

Quantity *

Message

II. Contact details

Name *

Email address *

Company/Organization

Phone

III. Ship To

Address *

City *

State/Province *

Zip/Post code *

Country *

Attn Name *

Phone# *

IV. Bill To Same as Shipping Address